Chemplast SanmarQ1 FY27
Chemplast Sanmar Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹179Market Cap: ₹2.8K CrSector: Chemicals & Petrochemicals
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- →Specialty Chemicals segment shows strong growth with 21% YoY volume increase in Q1 FY27; expected to continue ramping up with 14 commercial molecules and ~50 in development across agchem, pharma, and specialty sectors.
- →Custom Manufacturing (CMCD) business has a strong order book and is on track to achieve INR1,000 crores revenue target; ramp-up of new capacities progressing with full utilization expected by FY27 end.
- →Suspension PVC segment facing short-term challenges but expected to improve from Q3 FY27 onwards due to better PVC/VCM spreads supported by protective duties and market recovery.
- →Paste PVC realization and margins improving, aided by writ petition outcomes; capacity debottlenecking completed, supporting volume growth and better spreads.
- →R32 refrigerant gas production capacity of 14,000 tons to be fully commissioned by FY27 end with a go-to-market strategy targeting both domestic and international sales.
Margin guidance
Category 3- →Specialty Chemicals segment shows healthy 21% YoY volume growth with a strong order book, expected to drive profitable growth.
- →Custom Manufacturing (CMCD) pipeline robust with 50 molecules in development; revenue target of INR 1,000 crores over next 3 years primarily from agchem.
- →Four key positive triggers for EBITDA breakeven anticipated by Q3 FY27:
- → - Improved Suspension PVC spreads (~$160 India spread) supported by customs duty reinstatement and MIP.
- → - Paste PVC realizations improving post writ filed for antidumping duties.
- → - CMCD business ramp-up with commercialization of molecules and better utilization.
- → - Refrigerant gas (R32) capacity ramp-up expected by end FY27, contributing profitable margins.
- →Onerous contract provisions largely reversed, improving financial health.
- →Operating cash flow expected to improve with business ramp-up, aiding debt servicing without additional capital.
- →Overall, management expects a positive turnaround and reasonable performance from Q3 FY27 onwards.
3 more insights locked — sign up free to unlock
Fundraise plans
- Chemplast Sanmar has sufficient liquidity from conserved cash and current accruals to service all debt obligations; no immediate cause for concern regarding debt servicing.
- The company has positive operating cash flow but free cash flow remains negative due to growth capex.
- There is no explicit mention of plans for new fundraising through equity or debt during the call.
- The management indicates they can complete committed growth capex and debt repayments with existing resources without requiring additional capital, dilution, or external funding.
In summary, as of the August 2026 call, Chemplast Sanmar Limited does not indicate plans for new fundraising through debt or equity, relying instead on internal accruals and cash reserves.
Order book
Yes- →Custom Manufacturing business has a good order book with strong outlook and performance in Q1.
- →The CMCD (Custom Manufacturing & Development) segment has a healthy order book supporting 60-70% utilization of commissioned assets.
- →Currently, 14 molecules are in commercial production with around 50 molecules in various development stages in the pipeline.
- →Strong order backlog exists for the remaining 9 months of the year.
- →The business anticipates continued ramp-up and commercialization of additional molecules in the coming quarters.
- →Active efforts are underway to diversify beyond agchem to pharma and specialty chemicals with projects in progress.
- →Business development activities in Europe and Japan are ongoing for expanding client base and product range.
- →Overall, the company is confident of maintaining healthy order inflows and sustained growth in the CMCD segment going forward.
Capex plans
Yes- Chemplast Sanmar is investing in capacity expansion in the specialty chemicals segment to drive profitable growth.
- The Custom Manufacturing Chemicals Division (CMCD) capacity has expanded significantly, for example from roughly 1,100 tons to 5,400 tons.
- Resources have been invested in Europe and Japan to support business development and possibly diversify beyond agrochemicals into pharmaceuticals and specialty chemicals.
- The company is on track to commission 14,000 tons of refrigerant gas (R32) capacity by the end of the current fiscal year.
- Capex for growth is ongoing, with negative free cash flows due to investments, but liquidity and cash conservation help manage debt servicing.
- The committee of independent directors is evaluating strategic options to enhance long-term value, indicating possible future strategic investments or decisions.
Overall, significant capital investments are focused on specialty chemicals, capacity expansion, and geographic market diversification.
How does Chemplast Sanmar rank vs peers in Chemicals & Petrochemicals?
Pro feature1Chemplast Sanmar
Rev 3Mar 3
See full Chemicals & Petrochemicals sector rankings
How does Chemplast Sanmar rank in Chemicals & Petrochemicals?
Compare Chemplast Sanmar against every Chemicals & Petrochemicals company (Q1 FY27) on revenue, margins and earnings-call signals.